REGULATORY

• Vonoprazan Gets Panel Backing for Rx-to-OTC Switch
  August 25, 2025

• PMDA’s “Early Considerations” Start to Pay Off with Faster Reviews
  August 22, 2025

• Japan Mulls Preferential R&D Tax Credits for Strategic Technologies in FY2026 Reform Talks
  August 22, 2025

• AMED to Put Practicality First in Project Selection: Ecosystem Coordinator
  August 21, 2025

• MHLW FY2026 Budget Request to Focus on Clinical Trials, Early Regulatory Support
  August 21, 2025

• Japan Moves to Bolster R&D and Stockpiling of Crisis-Response Medicines
  August 20, 2025

• Astellas’ Izervay, Otsuka’s Nexletol among New Drugs Up for Japan Panel Review; Eylea Biosimilars Also on Agenda
  August 19, 2025

• MHLW Official Vows Steady Implementation of Amended PMD Act
  August 19, 2025

• Japan Weighs Legal Framework for Pharmaceutical Data Protection; JPMA Sees Opportunity for Reform
  August 19, 2025

• MHLW’s New Pharma Chief Pledges Safer, More Accessible Drug Environment
  August 19, 2025

• Nipro Secures AG for Forxiga, Sawai and Teva Takeda Go Without Hydrate
  August 18, 2025

• Japan Approves First SGLT2 Generics, 12 Firms Pile into Vimpat Ahead of December Listing
  August 18, 2025

• MHLW Working Group Sets Policy for Revising List of “Stable Supply Medicines”
  August 18, 2025

• Novartis’ Radioligand Therapy, Other New Meds Up for Japan Panel Review on Aug. 22
  August 12, 2025

• Japan Nears Approval for 1st Biosimilars of Actemra, Simponi, and Ranmark
  August 12, 2025

• Japan Approves FY2026 Budget Guidelines, Natural Increase at 400 Billion Yen
  August 12, 2025

• PMDA Flags New Potential Risks for RAS Agents and Others
  August 12, 2025

• Japan Approves MSD’s 21-Valent Pneumococcal Vaccine
  August 8, 2025

• Public-Private Council WG to Focus on Innovation Evaluation for FY2026 Reform: Official
  August 8, 2025

• Chuikyo Approves Insurance Coverage for 4 In Vitro Diagnostics
  August 8, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• …
• Next ›
• 最終 »